These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
214 related articles for article (PubMed ID: 21345133)
1. From traditional molecular biology to network oncology. Ziogas DE; Katsios C; Roukos DH Future Oncol; 2011 Feb; 7(2):155-9. PubMed ID: 21345133 [No Abstract] [Full Text] [Related]
2. Targeted therapy: overcoming drug resistance with clinical cancer genome. Ziogas DE; Katsios CS; Tzaphlidou M; Roukos DH Expert Rev Anticancer Ther; 2012 Jul; 12(7):861-4. PubMed ID: 22845399 [No Abstract] [Full Text] [Related]
3. Somatic alterations as the basis for resistance to targeted therapies. Blair BG; Bardelli A; Park BH J Pathol; 2014 Jan; 232(2):244-54. PubMed ID: 24114654 [TBL] [Abstract][Full Text] [Related]
4. Recent developments in cancer therapy and why we need a human cancer genome project. Becker GJ J Am Coll Radiol; 2005 Nov; 2(11):887-8. PubMed ID: 17411961 [No Abstract] [Full Text] [Related]
5. Mechanisms of acquired resistance to targeted cancer therapies. Lackner MR; Wilson TR; Settleman J Future Oncol; 2012 Aug; 8(8):999-1014. PubMed ID: 22894672 [TBL] [Abstract][Full Text] [Related]
11. The path to oncology drug target validation: an industry perspective. Cortés-Cros M; Schmelzle T; Stucke VM; Hofmann F Methods Mol Biol; 2013; 986():3-13. PubMed ID: 23436402 [TBL] [Abstract][Full Text] [Related]
12. Oncology. Are Voltaire and Rousseau now wrong? Raghavan D Lancet; 1996 Dec 21-28; 348 Suppl 2():sII17. PubMed ID: 8973495 [No Abstract] [Full Text] [Related]
13. Recent advances in apoptosis, mitochondria and drug resistance in cancer cells. Indran IR; Tufo G; Pervaiz S; Brenner C Biochim Biophys Acta; 2011 Jun; 1807(6):735-45. PubMed ID: 21453675 [TBL] [Abstract][Full Text] [Related]
14. Clinical relevance of P-glycoprotein with respect to the application of resistance modifiers. Scheulen ME Int J Clin Pharmacol Ther; 1998 Jan; 36(1):41-5. PubMed ID: 9476147 [No Abstract] [Full Text] [Related]
15. Understanding resistance to targeted cancer drugs through loss of function genetic screens. Berns K; Bernards R Drug Resist Updat; 2012 Oct; 15(5-6):268-75. PubMed ID: 23142522 [TBL] [Abstract][Full Text] [Related]
16. [Study on action mechanism of adjuvant therapeutic effect compound Ejiao slurry in treating cancers based on network pharmacology]. Xu HY; Wang SS; Yang HJ; Bian BL; Tian SS; Wang DL; Lu P; Zhou XS; You JH; Huang LQ Zhongguo Zhong Yao Za Zhi; 2014 Aug; 39(16):3148-51. PubMed ID: 25509304 [TBL] [Abstract][Full Text] [Related]
17. Preface: National Cancer Act. Smalley KS Adv Pharmacol; 2012; 65():xi-xiii. PubMed ID: 22959037 [No Abstract] [Full Text] [Related]
18. [Advances in medical oncology]. Shi YK Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2006 Jun; 28(3):305-10. PubMed ID: 16900620 [TBL] [Abstract][Full Text] [Related]
19. Canonical WNT signaling pathway and human AREG. Katoh Y; Katoh M Int J Mol Med; 2006 Jun; 17(6):1163-6. PubMed ID: 16685431 [TBL] [Abstract][Full Text] [Related]